Part 1 · What the company is worth
Overview
No description available.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Limited financial data available (0% of metrics). Scores may not accurately reflect this company's fundamentals.
Balance Sheet & Liquidity
Revenue
-
Net Income
-
Free Cash Flow
-
Total Equity
-
Total Liabilities
-
Current Ratio
4.44
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Valuation Metrics
P/E Ratio
-
ROE
-55.5%
P/B Ratio
-
P/FCF
-
Gross Margin
-
ROIC
-
Profitability Radar
Value Creation (Economic Moat)
ROIC
-
WACC
8.0%
ROIC − WACC
-
Fundamental Analysis Criteria
Passed (0)
Failed (0)
Unavailable (1)
- Error fetching data
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Buying back shares. Shareholder friendly
Governance
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for ACLX, sourced from Markets Gazette.
- 3/2/2026POSITIVEArcellx President Sells $10M Worth of Shares After Acquisition Announcement
Arcellx Inc. shares have experienced a remarkable 75% surge in 2026, a significant jump directly linked to the company's impending acquisition, which will result in its delisting from the market. This development typically provides a premium for shareholders, a common outcome in M&A transactions. The President of Arcellx capitalized on this situation by selling $10 million worth of shares. While insider sales can sometimes be viewed negatively, in this context, it appears to be a logical consequence of the acquisition, which has already propelled the stock to elevated levels, making it soon untradable on public exchanges.
- 2/25/2026POSITIVEGilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy
Markets Gazette reports that Arcellx (ACLX) shares experienced a modest uplift following the announcement of its acquisition by Gilead Sciences. The biopharmaceutical giant has agreed to purchase Arcellx for a substantial $7.8 billion, translating to $115 per share in cash. This strategic move underscores Gilead's significant investment in the burgeoning field of cancer therapy, particularly in Arcellx's innovative pipeline. For investors, this deal represents a clear positive catalyst for Arcellx, offering a premium valuation and immediate liquidity, while positioning Gilead for potential long-term growth in oncology.
via Markets Gazette